GLP-1 agonists – of which Novo Nordisk’s Ozempic and Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide) are the most ...

Novo Nordisk A/S (NVO)'s share was trading at $109.09 as of Nov ... pricing dynamics linked to increased patient ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

Diabetes and weight-loss drug tirzepatide (Mounjaro, Zepbound) was listed as a contributing factor in the death of a 58-year-old nurse from Scotland who died of multiple organ failure, septic shock, ...

If you said diabetes, you're right -- a new study finds diabetes costs $101 billion annually in diagnosis and treatment and ...

Wegovy (semaglutide) is a GLP-1 receptor agonist that’s ... In a year-long study funded by Saxenda’s manufacturer, Novo Nordisk, people without diabetes who took Saxenda lost an average of 18 pounds.

A Scandinavian economic behemoth, Novo Nordisk is the highest valued company in Europe at over $500 billion, which exceeds ...

Ozempic, Mounjaro, Wegovy, Victoza and Trulicity are part of a class of ... consultation with a healthcare professional and ...

Lars Fruergaard Jørgensen began his career at Novo Nordisk as an economist in the health care, economy, and planning ...